Integrated biopharmaceutical company ThromboGenics has obtained Health Canada approval for Jetrea (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA). Launch of the drug in Canada will be conducted by Alcon, ...
Biopharmaceutical company ThromboGenics' Jetrea has received approval from UK's National Institute for Health and Care Excellence (NICE) in the treatment of some adults with vitreomacular traction (VMT), a rare eye condition. Known as ...
Tags: Eye Condition Treatment, Medicine
Integrated biopharmaceutical company ThromboGenics has announced the launch of Jetrea in Denmark and Sweden by Alcon, a division of Novartis. Alcon expects to roll out the European Commission approved Jetrea, which is indicated for the ...
The European Commission has approved ThromboGenics' Jetrea (ocriplasmin) for the treatment of vitreomacular traction (VMT), including when coupled with macular hole of diameter less than or equal to 400 microns, in the European Union (EU). ...
Tags: ThromboGenics Jetrea, vitreomacular traction treatment, drug